Research
Hormonal
Newer anti-obesity medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.
Practitioners should consider these medications for patients seeking significant weight loss.
StrongSupportsmedium confidence
newer medications such as semaglutide and tirzepatide have shown greater than 15% reduction in baseline weight.
Why this rating
The claim is based on a review of pharmacological treatments for obesity.
Source
Management of obesity
Lourdes Cross · American Journal of Health-System Pharmacy · 2024
DOI 10.1093/ajhp/zxae273
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →